Navigation Links
Elusys' Anthrax Anti-Toxin, Anthim(TM), Enters Second Phase I Clinical Study
Date:4/20/2009

tection when given within 12 hours of an anthrax exposure. These results have been consistent across studies whether Anthim was used with or without antibiotics. Our first Phase I human safety study demonstrated that Anthim is safe and well-tolerated as a monotherapy and as a combined therapy with the antibiotic ciprofloxacin. This second study will continue to expand our safety database and provide additional pharmacokinetic data."

Dr. Posillico added, "Death from the effects of anthrax toxin can occur in a few days if patients are not treated quickly. We are very excited about Anthim because the results of all of our studies show that treatment with Anthim has the potential to provide significant therapeutic benefit for people infected with anthrax in a bioterrorism emergency." Currently antibiotics represent the only therapeutic option for anthrax infection. Antibiotics target the bacteria, but can still fail to prevent death from the damaging effects of anthrax toxins. In addition, antibiotic resistant strains of anthrax could be used in a bioterror attack, making the medical need for anti-toxin therapy even more acute.

Anthim Background

Anthim is a high-affinity, humanized and deimmunized monoclonal antibody that targets the protective antigen of B. anthracis and neutralizes the lethal effects of anthrax toxins. It is being developed for prevention and treatment of inhalation anthrax. Anthim has been granted Fast-Track status and Orphan Drug Designation by the FDA. The National Institutes of Health and the Department of Defense have awarded Elusys a total of $34 million for the development of Anthim, of which $12 million was awarded in September 2007 under contract #HHSN272200700035 from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and the Biomedical Advanced Research and Development Authority (BARDA), part of the Department of Hea
'/>"/>

SOURCE Elusys Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Companys Anthrax Therapeutic
2. Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
3. New Approach to Treating Anthrax Significantly Improves Survival Rates in Pivotal Efficacy Studies
4. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Another LNA-based RNA Inhibitor Enters Clinical Trials
7. Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study
8. ESBATechs Antibody Fragment Enters Phase Ib/IIa in Ophthalmology
9. ESBATechs Antibody Fragment Enters Phase I/IIa Clinical Development in Osteoarthritis with the Potential for Disease-Modifying Activity
10. ELAD(R) Liver Support System Study Initiated at Multiple U.S. Centers
11. PreMD Inc. Enters Clinical Study with Cosmetics Conglomerate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... 2015 Helping seniors stay as independent ... be a full-time job for families and caregivers. ... gap when they can,t be with their aging ... eHeart Health Monitoring, LLC , not all personal ... Photo - ...
(Date:5/26/2015)... , May 26, 2015 Xencor, Inc. ... engineered monoclonal antibodies for the treatment of autoimmune diseases, ... Bassil Dahiyat , President and Chief Executive Officer, ... Tuesday, June 2, 2015 at 8:30 a.m. ET in ... A live audio webcast of the presentation will be ...
(Date:5/26/2015)... , May 26, 2015 ... clinical-stage biopharmaceutical company leveraging its molecular adhesion and ... for sickle cell disease, heart failure, and arterial ... open-label, multicenter Phase 3 extension study of vepoloxamer ... "EPIC-E."  The study will enroll patients who have ...
Breaking Medicine Technology:eHeart Health Monitoring Gives Tips on Choosing the Right Personal Alert System for Aging Loved Ones 2eHeart Health Monitoring Gives Tips on Choosing the Right Personal Alert System for Aging Loved Ones 3eHeart Health Monitoring Gives Tips on Choosing the Right Personal Alert System for Aging Loved Ones 4Xencor to Present at Jefferies 2015 Healthcare Conference 2Mast Therapeutics Announces Initiation Of EPIC-E Study 2Mast Therapeutics Announces Initiation Of EPIC-E Study 3Mast Therapeutics Announces Initiation Of EPIC-E Study 4Mast Therapeutics Announces Initiation Of EPIC-E Study 5
... 15, 2011 Thorne Research, Inc., a leader ... the establishment of a new joint venture with ... medical information, consulting services and products focused on ... care. Health Elements brings together two of the ...
... SHENZHEN, China, April 15, 2011 /PRNewswire-Asia-FirstCall/ -- Tongjitang Chinese ... TCM ), announced today the completion of its acquisition ... company ("Hanmax"), and Fosun Industrial Co., Limited, a company ... the acquisition, the Company became a wholly owned subsidiary ...
Cached Medicine Technology:Thorne Research and Integrative Health Resources Establish Joint Venture to Provide Full Range of Services in Practice Development, Patient and Clinician Education, and Access to Nutritional Supplements in Integrative Medicine 2Thorne Research and Integrative Health Resources Establish Joint Venture to Provide Full Range of Services in Practice Development, Patient and Clinician Education, and Access to Nutritional Supplements in Integrative Medicine 3Thorne Research and Integrative Health Resources Establish Joint Venture to Provide Full Range of Services in Practice Development, Patient and Clinician Education, and Access to Nutritional Supplements in Integrative Medicine 4Tongjitang Chinese Medicines Company Announces Closing of Merger and Intent to Delist from the NYSE 2Tongjitang Chinese Medicines Company Announces Closing of Merger and Intent to Delist from the NYSE 3
(Date:5/26/2015)... 26, 2015 Pasadena porcelain veneers ... dental cleanings with cosmetic treatments. Cosmetic dentistry is becoming ... Dentistry , “We are committed to providing you with ... outstanding customer service and a smile of a lifetime ... your smiles but to change your life,” explains Dr. ...
(Date:5/26/2015)... Oklahoma (PRWEB) May 26, 2015 National ... May every year. It is supported by the ... dedicated to raising public awareness of, and action about, ... and community organizations and coalitions are encouraged to join ... substance abuse and related issues, and in building community ...
(Date:5/26/2015)... Award-winning travel photographer and life coach Raul Espinoza ... will connect viewers to the beauty of the world while ... years, Raul has traveled the world documenting lives, and then ... not bounded by our circumstances. , “KAWSAY” means ... Bolivia. The photo gallery show by the same name will ...
(Date:5/26/2015)... CA (PRWEB) May 26, 2015 ProTrailer ... for Final Cut Pro X . This ... to simple and elegantly styled text. , ProTrailer ... seconds. , ProTrailer Network can easily complement any form ... desired and within seconds can make professional looking openers. ...
(Date:5/26/2015)... PA (PRWEB) May 26, 2015 ... XML Editor with the Vasont® CCMS to make ... Vasont Systems, a top component content management system ... Integrator (VUI) extension supports oXygen XML Editor Version ... The Vasont Universal Integrator extension merges key editorial ...
Breaking Medicine News(10 mins):Health News:Pasadena Porcelain Veneers Expert, Marine Martirosyan DDS, is Now Offering Complimentary Dental Cleaning with Cosmetic Treatments 2Health News:Narconon Arrowhead Takes Part in National Prevention Week 2Health News:Narconon Arrowhead Takes Part in National Prevention Week 3Health News:A Photographer & Two Educational Organiazations Join to Make a Difference in Our Youth 2Health News:Developers at Pixel Film Studios Release ProTrailer Network for Final Cut Pro X 2Health News:Vasont Systems Certifies the Integration between the Vasont® Component Content Management System and oXygen® XML Editor 17.0 2
... large biotech company began collecting ePRO (electronic patient ... in clinical trials around the world. Recently, assistek,s ... assisTek system compared to what it would have ... questionnaires. The results showed that assisTek,s ePRO data ...
... has led the University of California, San Francisco for the past 10 ... 30, 2009. , ... (Vocus) October, 24, 2008 -- Chancellor J. Michael ... the past 10 years, today announced plans to step down from his ...
... Nov 14-15 Conference - including free sessions ... WASHINGTON, Oct. 23 This November, ... Disorder, will host its 20th annual,international conference ... The,three-day CHADD conference offers an exceptional opportunity ...
... of visitors to Internet drug outlets nearly tripling in ... than ever. Based on its,assessment of more than 1,000 ... Boards of Pharmacy(R) (NABP(R)) finds,that 97% of these sites ... federal laws or established patient safety and pharmacy practice,standards. ...
... FRANCISCO, Oct. 23 Halloween can be,filled with tricks ... for,children. The California Poison Control System (CPCS) urges parents ... fun while,decreasing risk., If parents have questions, the ... days a week for immediate expert help and information ...
... LAUDERDALE, Fla., Oct. 23 LifeSync Corporation,announced it ... MAGNET,which is comprised of 12,000 members in 20 ... and disposable ECG LeadWear(R) products., Shelley Hartman, ... enter into this agreement with MAGNET. MAGNET is ...
Cached Medicine News:Health News:assisTek's ePRO Biotech Clinical Trial Data Collection Saves Client $1.6 Million Over Paper Questionnaires 2Health News:UCSF Chancellor J. Michael Bishop Announces Plan To Step Down 2Health News:UCSF Chancellor J. Michael Bishop Announces Plan To Step Down 3Health News:UCSF Chancellor J. Michael Bishop Announces Plan To Step Down 4Health News:UCSF Chancellor J. Michael Bishop Announces Plan To Step Down 5Health News:UCSF Chancellor J. Michael Bishop Announces Plan To Step Down 6Health News:UCSF Chancellor J. Michael Bishop Announces Plan To Step Down 7Health News:CHADD to Host International Conference on AD/HD in Anaheim, CA; Olympian Bruce Jenner to Keynote 2Health News:NABP Findings Underscore Dangers of Purchasing Prescription Medicine Online and From Foreign Sources 2Health News:NABP Findings Underscore Dangers of Purchasing Prescription Medicine Online and From Foreign Sources 3Health News:Celebrate Halloween Safely This Year With Tips From the California Poison Control System 2
To prevent retraction of the conjunctival cul-de-sacs without touching the cornea....
For Frontalis Suspension in patients with significant ptosis and poor levator function....
For enucleation/evisceration....
... A new Transnasal Lacrimal Stent has been ... B. Becker, M.D., the Transnasal Lacrimal Stent addressed ... and other forms of endoscopic DCR. Brought in ... relatively large diameter. Because there is no need ...
Medicine Products: